Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

14 Feb 2018

Immunology portfolio yielded 14% sales growth in 2017, led by growing subcutaneous immunoglobulins and a still-rising HAE franchise. Dry eye drug Xiidra was another 2017 growth catalyst.

Shire CEO Flemming Ornskov • Source: Source: Shire PLC

Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio

More from Earnings

More from Business